AN2 Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 4.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 170.95M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company’s initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has ...